Active Ingredient(s):Avacopan FDA Approved: * October 7, 2021 Pharm Company: *CHEMOCENTRYX
Avacopan, sold under the brand name Tavneos, is a medication used to treat anti-neutrophil cytoplasmic autoantibody-associated vasculitis.
Avacopan was approved for medical use in Japan in September 2021, and in the United States in October 2021. It is the first orally-administered inhibitor of the complement C5a receptor approved by the U.S. Food and Drug Administration (FDA).
* May have multiple approval dates, manufacturers, or labelers.